TWI301761B - Zinc-free and low-zinc insulin preparations having improved stability - Google Patents
Zinc-free and low-zinc insulin preparations having improved stability Download PDFInfo
- Publication number
- TWI301761B TWI301761B TW091105385A TW91105385A TWI301761B TW I301761 B TWI301761 B TW I301761B TW 091105385 A TW091105385 A TW 091105385A TW 91105385 A TW91105385 A TW 91105385A TW I301761 B TWI301761 B TW I301761B
- Authority
- TW
- Taiwan
- Prior art keywords
- insulin
- zinc
- pharmaceutical composition
- concentration
- patent application
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 161
- 102000004877 Insulin Human genes 0.000 title claims description 63
- 108090001061 Insulin Proteins 0.000 title claims description 63
- 229940125396 insulin Drugs 0.000 title claims description 62
- 239000011701 zinc Substances 0.000 title claims description 26
- 229910052725 zinc Inorganic materials 0.000 title claims description 26
- 238000002360 preparation method Methods 0.000 title description 37
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 23
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 23
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 19
- 239000004026 insulin derivative Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000004094 surface-active agent Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 230000002079 cooperative effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims description 2
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 claims description 2
- 229930003836 cresol Natural products 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- 229910052684 Cerium Inorganic materials 0.000 claims 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 16
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 229920001983 poloxamer Polymers 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000013020 final formulation Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 12
- 229960000502 poloxamer Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- -1 that is Chemical compound 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 239000004475 Arginine Chemical group 0.000 description 7
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical group [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 235000018977 lysine Nutrition 0.000 description 7
- 229940068977 polysorbate 20 Drugs 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 229960000281 trometamol Drugs 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000003093 cationic surfactant Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 238000002309 gasification Methods 0.000 description 2
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 2
- 229960002068 insulin lispro Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 101100124528 Caenorhabditis elegans hmr-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000052651 Pancreatic hormone Human genes 0.000 description 1
- 101800001268 Pancreatic hormone Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- RSWIRYGYWCMQOG-UHFFFAOYSA-N acridine-1-thiol Chemical compound C1=CC=C2C=C3C(S)=CC=CC3=NC2=C1 RSWIRYGYWCMQOG-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940080284 cetyl sulfate Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- LPTIRUACFKQDHZ-UHFFFAOYSA-N hexadecyl sulfate;hydron Chemical compound CCCCCCCCCCCCCCCCOS(O)(=O)=O LPTIRUACFKQDHZ-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 108010066090 neutral insulin Proteins 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 229940032957 pancreatic hormone Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 150000003752 zinc compounds Chemical group 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
1301761
、發明說明（！） 發明之概球 本發明為有關於一種增進穩定性之醫藥衾 成物，其包括選自下列之多肽：胰島素(例如: 類騰島素、牛胰島素或豬胰島素）、騰島素㈣ ，、騰島素衍生物、活性胰島素代謝物或其4 組合；一種界面活性劑或許多界面活性劑之金 ，，和選擇性添加一種防腐劑或許多防腐劑3 砠合’以及選擇性添加一種等壓劑、緩衝劑a 賦形劑或其之組合，此醫藥組成物為低鋅或; 鋅。此配方可應用於糖尿病之治療，以及特另 適用於胰島素泵、冑、注射器、吸入器或需名 增加物理穩定性之製劑。本發明同樣為有關友 -種非經口製劑’其含上述可使用於糖尿病戈 配方，以及製備該製劑和增進糖尿病製劑之浪 定性的方法。 經濟部智慧財產局員工消费合作社印製 ^全球約有一億二千萬的人口罹患糖尿病。 這些患者中約一千二百萬的人屬於第一型糖肩 病，其目前唯一治療方法祗有補充内分泌胰磨 素分泌的缺乏。患者終身仰賴每天數次的胰磨 素/射和第一型糖尿病比較，第二型糖尿病 基本上並非胰島素的缺乏，大部分以胰島素％ 療的病例配合口服抗糖尿劑即可得到良好治療 -3- 1301761 五 發明說明（2) A7 B7 效果，特別是在疾病的惡化期。 健康人之胰臟所分泌之胰島素和血糖濃度 有、绝胃的關係。例如在用餐後血糖濃度昇高 時’騰島素之分泌有迅速增加之代償作用。在 禁食期間，細胞質胰島素降至基礎值而可持續 供應葡萄糖至胰島素-敏感之器官和組織，並且 可降低晚間肝糖之產量。大部分從皮下投與以 取代内源性胰島素分泌之外源性胰島素並無法 達到上述血糖之生理調節上的品質Q其通常會 造成血糖上下起伏之波動，其嚴重時有導致死 亡的危險。此外，無初症狀之經年性血糖濃度 過兩仍被視為健康上的一種威脅。在美國大規 模的DCCT研究[糖尿病之控制和併發症試驗研 究小組（1993)·心g/. «/, MeA329,977〜986]清楚說 經濟部智慧財產局員工消費合作杜印裝 月陵性血糖濃度幵咼為造成糖尿病末期損傷的 主要原因。糖尿病未期的損傷主要為微血管和 大血管的病變，在某些特定情況下會呈現視網 膜病、腎病或神經變性病而導致失明，腎衰竭 和四肢病變，以及伴隨心臟血管疾病危險指數 的增加。溽於此，故糖尿病改善療法之主要目 標為使弟血糠儘量保持接近其生理範圍。根據 此胰島素治療觀念的強化，故每天必需持續注 簡4- A7 B7 1301761 ^__-_ 五、發明說明（3) 射速效和緩效騰島素製劑。為了避免餐後血糖 的增加，速效之糖尿病製劑必需於用餐時服 用。缓'效之胰島素製劑主要目的為確保基本胰 島素之供應’特別是避免晚上的低叙糖症。 胰島素為具有51個胺基酸的多肽，其分成 兩種胺基酸鏈：具有21個胺基酸之A鏈和具有 30個胺基酸之B鏈。其藉由兩個二硫化物橋相 互連接。胰島素用於糖尿病之洽療已行之务 年&此處不僅使用天然之膜島素，最近使亦用 胰島素之衍生物和其類似物。 胰島素類似物為天然之胰島素，亦即為人 類胰島素或動物胰島素，其不同在於至少一天 然胺基酸殘基被其它之按基酸殘基所取代，和/ 或從對應或相同之天然胰島素添加/移除至少一 胺基酸殘基。非天然之胺基酸殘基亦可被添加 和/或取代。 經濟部智慧財威扃員工消貲合作社印载 胰島素衍生物為天然胰島素或胰島素類似 物之衍生物，其經過化學修飾而得。此化學修 飾包括，例如，一個或以上的胺基酸添加一個 或以上的特殊化學基。 通常，騰島素衍生物和胰島素類似物和人 類胰島素比較或多或少都經過修飾。 -5- 1301761 A7 ___B7 五、發明說明（4) EP 0 214 826、EP 0 375 437 和 EP 0 678 522描述胰島素具有加速作用的效果。EP 0 124 826為特別有關B27和B28之取代物。EP 0 678 522說明具有各種胺基酸於B29位置之胰島素類 似物，其以脯胺酸（proline)較佳，但非麩胺酸 (glutamic acid)。EP 〇 375 437 述及包括具有離 胺酸（lysine)或精胺酸（arginine)於B28位置之胰 島素類似物，其可選擇另外於B3和/或A21位 置進行修飾。 EP 0 419 504中揭示具有對抗化學修飾之保 護的胰島素類似物，其B3位置之精胺酸以及位 於A5、A15、A18或A21位置至少有一個或更 多的胺基酸被修飾。 經濟部智慧財產局員工消费合作社印製. WO 92/00321中說明B1〜B6位置至少有一 個胺基酸被離胺酸或精胺酸所取代。根據W0 92/00321所述，此類之胰島素具有延長效果的 作用。 市售之天然胰島素製劑有不同於原始胰島 素（例如牛、豬、人類勝島素）之胰島素取代物和 組成，同時亦影響其效果（產生作用和作用時 間）。組合各種不同胰島素製劑’可建立近似生 理狀態的不同作用模式和血糖值。有時，除了 -6- 1301761 Α7 Β7 五、發明說明（5) 上述天然胰島素之外，已上市之胰島素街生物 製劑或胰島素類似物在動力學上亦經過改良。 今曰之DNA重組技術，對製備此類改良姨島素 而言已漸趨成熟。其包括”單體胰島素類似 物’’，例如具有速效之胰島素Lispro、騰島素 Aspart和HMR 1964[人類胰島素離胺酸（B3)，麵 胺酸（B29)〗，以及具有長效之胰島素Giargin。 或 用 均 泵 學 除了作用時間之外，製劑之穩定性對病人 而言亦非常重要。增進胰島素配方之穩定性， 對露暴於特殊機械緊迫或高溫下之製劑而言有 助於增加其長期之物理穩定性。這些情形 括’例如’筆形、吸入系統、無針注射系統 胰島素泵之騰島素投藥系％。胰島素泵可利 穿戴或植入病人體内之方式。上述兩種方式 使製劑必需在承受體溫和振動之下而不影響 浦之輸送動作，因於i v泰a l & 經濟部智慧財產局員工消费合作社印製 ^ 岛此其必需有非常高的熱化， 抗力。由於胰島辛签〆 系幸（了樾棄式和可回收式筆）同 樣必需穿戴在身上，丛女 A _ 故亦必需有相同之抗力 定 兀^之製劑在上述情 I It况下均不具有足夠之穩 性 胰島素以穩定 > 人^ v, . ^ 鋅六聚物（hexamers)的形 式存在於藥用潘疮μα 度的中性溶液中，其由3個相 -7· A7 B7 1301761 五、發明說明（6 ) 同之二聚物（dimmer)單位所組成[Brange等人， 糖尿病之看護，13 : 923〜954 (1990)]。藉胺基 酸順序之修飾，可減少胰島素之結合。因此， 主要以单體形式存在之騰島素類似物，例如 Lispro，可更迅速地被吸收而呈現較短的作用時 經濟部智慧財產局員工消费合作社印製 間（HPT Ammon和C· Werning;抗糖尿病；第2 版；Wiss· Verl.-Ges· Stuttgart，2000 ,第 94.f 頁）。然而，以單體或雙體形式存在之速效胰島 素類似物的穩定性較低並且在熱和機械緊迫下 較易聚集。此可由其混濁狀和出現不可溶解之 沉殿物而得知（Bakaysa等人，美國專利號瑪 547497 8)。這些較高分子量之變形產物（雙體、 三體、多體）和聚積物不僅會降低胰島素之投藥 劑量，亦會導致病人之刺激或免疫反應。該不 可溶解之聚積物甚至會影響以及導致泵浦插管 和導管之阻塞。由於鋅可增加胰島素之穩定 性，而無鋅或低鋅胰島素製劑以及胰島素類似 物則對穩定性特別敏感。速效之單體胰島素類 似物由於其單體胰島素易形成不溶性之聚積 物，因此不具物理上的穩定性。為了維持騰島 素製劑之品質，故必需避免其形成聚積物。 有許多方法可增進胰島素之穩定性。國際 -8- A7 B7 1301761 五、發明說明（Ο 專利申請案WO98/56406中述及以TRIS或精胺 酸緩衝液增加騰島素之穩定性。美國專利 5866538述及一種含甘油和5〜100mM(毫莫耳濃 度）之胰島素製劑，其具有增進穩定性之效果。 美國專利5948751述及一種增加物理穩定性之 胰島素製劑，其添加了甘露糖醇或其它類似之 糖類。含辞之胰島素溶液添加過量之鋅時同樣 可增加其穩定性（J· Brange等人，糖尿病醫學， 3 : 532〜5 36，1986)。酸驗度和各種賦形劑對騰 島素製劑之穩定性的影響亦已被廣為討論（j.
Brange 和 L. Langkjaer，Acta Pharm. Nordica 4 : 149〜158) 〇 經濟部智慧財產局貝工消费合作社印製 這些增加穩定性的方法通常無法跟隨日漸 增加之需求的腳步（增進其於室内或體溫以及在 機械緊迫下之穩定性），對物理緊迫特別敏感之，， 單體”胰島素或速效胰島素而言亦是如此。此 外’所有市售含鋅之胰島素製劑，其添加之鋅 全為穩定製劑之用途。因此，Bakaysa等人於美 國專利5474978中述及增進穩定性之胰島素複 合物，其含6個胰島素類似物單體、2個鋅原子 和至少3個苯酚防腐劑分子。這些配方可另外 添加生理學上可接受之缓衝劑和防腐劑。然 -9- 1301761 五、發明說明（s) 經濟部智慧財產局員工消費合作社印製 而’如果在不添加鋅的情 無法達到可上市之要=:，上述之製劑均 在無辞的情況下會喪失其/姨島素Lispr。 rR . 畏失其物理上的穩定性 心等人，蛋白質科學（1996)，S : =21〜2531卜先前之技術中並未提及具有適當穩 疋性’特別是物理穩 咏* i 穩疋性，之有關低鋅或無鋅 胰島素配方。 因此本發明為根據此目標而發現一種無 辞胰島素製劑及其衍生物和類似物，並且其 具有極高之穩定性。 我們目前很驚訝地發現，添加例如 poloxamers 或聚山梨酸酯（p〇iys〇rbate)(TweenTM) 可戲劇化地增進胰島素製劑之穩定性，並且即 使無鋅之製劑亦具有極佳的穩定性，故其可被 用於注入泵或其它投藥系統中。這些製劑特別 是在緊迫之狀況下仍具有極高的穩定性。此原 理可應用於騰島素、胰島素類似物、胰島素衍 生物或其之混合物。 在中性溶液中，胰島素和鋅離子形成複 物。此時’在適當之鋅濃度下，6個胰島素分 和2個鋅離子可形成穩定之六聚物。形成此構 造時’鋅相對胰島素的濃度必需至少 裝 訂
4•I 合子 在 -10· A7 B7 1301761 i、發明說明（9) 0.4%(w/w)以上。此相當於製備100 IU/ml(國際 單位/毫升）之胰島素時，鋅之濃度必需約為 13pg/ml(微克/毫升）。過量之鋅（例如每一個六聚 物供應4個鋅離子）可更明顯增加其對物理緊迫 之穩定性[J· Brange等人，藉添加辞離子增進中 性胰島素之物理穩定性 ，Diabetic Md.3,532〜536(1986)〗。相較於低辞濃度之胰島 素（以重量計其<0·4%之胰島素），則產生較少之 六聚物。因此，會戲劇性地減低胰島素之穩定 性[J· Brange 和 L· Langkjaer ; 經濟部智慧財產局員工消費合作社印製 ，4 : 149〜15 8 (1992)]。此處，”無鋅，，或，，低 辞之含意為其相對騰島素之含量低於以重量計 0 4% ’其相對胰島素以重量計以低於0.2%較 佳°以胰島素製劑之慣例其每毫升含丨〇〇單位 (〇·6μιηο1/ηι1)，亦即，例如，相對1〇〇單位/ml /辰度之騰島素其鋅離子含量低於13pg/ml(〇 2 μπιοΐ/ηιΐ) ’其鋅離子以低於j 較佳0可加 入例如擰檬酸鹽（(：以“約或EDTA之含鋅複合物 以除去鋅離子，而使其無足夠之鋅離子形成胰 島素/鋅之六聚體複合物。 藥用製劑中含6〇〜6,000 nm〇l/ml(納莫耳/毫 升）之胰島素、胰島素代謝物、胰島素類似物或 -11 -
經濟部智慧財產局員工消费合作社印製 1301761 一胰島素衍生物，其以含24〇〜3 ,〇〇〇 nm〇l/ml較 佳。 可使用之界面活性劑特別指非離子或離子 (陰離子、陽離子或兩性離子）之界面活性劑而 言。特別以慣用之藥用界面活性劑較佳，舉例 而言，例如·· 驗金屬肥皂、胺肥息和驗土金屬肥阜I硬脂 酸酯、棕櫚酸酯、油酸酯、蓖麻酸酯 (ncinoleates)]、烷基硫酸酯和烷基亞磺酸酯 (alkylsulfonates)[月桂基硫酸鈉（sodium laurylsulfate)、硫酸鯨蠟鈉（s〇dium cetylsulfate)、硬脂硫酸鈉]、天然界面活性劑·[膽 汁酸鹽、皂苷、阿拉伯膠（gum arabic)]、陽離子 界面活性劑I烧基漠化物（alkonium bromides)、 錄蠛基ϋ比咬氣化物（cetylpyridinium chloride)、苯 扎溴銨（cetrimide)]、脂肪醇[鯨蠟醇（cetyl alcohol)、十八烧醇（stearyl alcohol)、膽固醇】、 多元醇之部分和脂肪酸酯，例如甘油、山梨糠 醇（sorbilol)和其類似物（Span®、Tween⑧、 Myrj^、Brij⑧）、Cremophor^i poloxamers。此藥 用組合中之界面活性劑的濃度為 〇.lpg/ml〜10,000gg/m卜以 lpg/mi〜U〇〇〇pg/ml 較
•12- A7 B7 1301761 五、發明說明（11) 佳。 此製劑中可添加防腐劑[例如苯鹼、甲苯 酚、對羥苯甲酸酯（parabens)】、等壓劑[例如甘 露糖醇、山梨糖醇、乳糖、葡萄糖、海藻糖 (trehalose)、氣化鈉、甘油]緩衝物質、鹽、酸和 鹼、和其它之賦形劑。這些物質在個別之製劑 中可單獨存在或任選之混合物。 甘油、葡萄糖、乳糖、山梨糖醇和甘露糖 醇慣常以100〜250mM(毫莫耳濃度）出現於藥用 製劑中，氣化鈉的濃度則可至150mM 〇例如磷 酸鹽、醋酸鹽、檸檬酸鹽、精胺酸、甘胺醯基 甘胺酸（glycylglycine)或TRIS(即2-胺-2-羥曱基-1,3-丙二醇）之緩衝劑和其相關鹽類之濃度為 5〜250mM，以10〜100mM較佳。 其它之賦形劑特別指鹽、離胺酸、魚精蛋 白（protamine)或 Surfer^。 經濟部智慧財產局員工消費合作社印製 因此本發明為有關一種醫藥組成物，其包 括選自含胰島素、胰島素類似物、胰島素衍生 物、活性胰島素代謝物或其組合之族群的多 肽；一種界面活性劑或許多界面活性劑之組 合；選擇性地添加防腐劑或許多防腐劑之組 合；以及選擇性地添加一種等壓劑、緩衝物質 -13- A7 B7 1301761 五、發明說明（12) 經濟部智慧財產局員工消费合作社印製 和/或其它之賦形劑或其之組合，此醫藥組成物 為無鋅或低鋅；此類藥用製劑之界面活性劑以 選自含鹼金屬肥皂、胺肥皂、鹼土金屬肥皂、 燒基硫酸酯、燒基亞續酸酯、天然界面活性 劑、陽離子界面活性劑、脂肪醇、例如甘油和 山梨糖醇之多元醇的部分和脂肪酸酯、多元醇 等之族群較佳；上述之肥息為選自含硬脂酸 酯、棕櫚酸酯、油酸酯、蓖麻酸酯之族群；該 烧基硫酸酯為選自含月桂基硫酸鈉、硫酸鯨蠛 納、硬脂硫酸鈉之族群；該天然界面活性劑為 選自含膽汁酸鹽、皂苷、阿拉伯膠、卵磷酯之 族群；該陽離子界面活性劑為選自含烷基溴化 物、録躐基吼啶氣化物、苯扎溴錄（Cetrimide<gi) 之族群；該脂肪醇為選自含鯨蠟醇、十八烷 醇、膽固醇之族群；該多元醇、甘油、山梨糖 醇之脂肪酸醋及醚類為選自含Span®、Tween⑥、 以㈣⑧、Brij⑧、cremophor⑧之族群；該多元醇為 選自含聚丙烯乙二醇（p〇lypr〇pylene glyc〇ls)、聚 乙稀乙一醇、pl〇iXamers 、 Pluronics 、 Teuomcs(特窻）之族群；該防腐劑為選自含苯 紛、甲苯齡、對羥苯曱酸酯之族群；該等壓劑 為選自含甘露糖醇、山梨糖醇、氣化鈉、甘油 -14- 301761 A7 B7 五 '發明說明（13) 經濟部智慧財產局員工消费合作社印製 之族群；該賦形劑為選自含緩衝物質、酸、鹼 之族群；該膜島素為天然之騰島素，例如人 類、牛或豬之臟島素；該胰島素類似物為選自 含甘胺酸（A21)、精胺酸（B31)、精胺酸（B32)、 人類胰島素、離胺酸（B3)、麩胺酸（B29)、人類 胰島素、離胺酸B28脯胺酸B29人類胰島素、B28 天門冬胺酸人類胰島素、人類胰島素，B28位置 之脯胺酸被天門冬胺酸、離胺酸、亮胺酸、纈 胺酸或丙胺酸所取代，以及在B29位置之離胺 酸被脯胺酸所取代、丙胺酸B26人類胰島素、 des(B28〜B3 0)人類胰島素、des(B27)人類胰島素 或des(B30)人類胰島素之族群；該胰島素衍生 物為選自含 B29-N·肉豆蔻醯基（myristoyl)-des(B30)人類胰島素、B29-N-軟脂醯基 (palmitoyl卜des(B30)人類胰島素、B29-N_肉豆蔻 醯基人類胰島素、B29-N·軟脂醯基人類胰島 素、B28-N-肉豆蔻醯基-離胺酸B28脯胺酸B29人 類胰島素、B28-N-軟脂醯基-離胺酸 B28 脯胺酸 B29 B29人類胰島素、B30-N-肉豆蔻醯基-蘇胺酸 離胺酸B3G人類胰島素、B30-N-軟脂醯基-蘇胺 酸B29離胺酸B30人類胰島素、B29-N-(N-軟脂醯 基_Υ·麩胺醯基）-des(B39)人類胰島素、B29-N· 裝 訂 -15· 經濟部智慧財產局員工消費合作社印製 1301761 Α7 ___ Β7 五、發明說明（14) (N-石膽酸醯基_γ_麩胺醯基）_des(B30)人類胰島 素、Β29-Ν-(ω-羧十七醯基）-des(B30)人類胰島素 和Β29-Ν-(ω-羧十七醯基）人類胰島素等之族 群。 本發明進一步為有關於上述之醫藥組成 物，其胰島素、騰島素類似物、活性胰島素代 謝物和/或胰島素衍生物之濃度為240〜3,000 nmol/ml(此相當於濃度1.4〜35 mg/ml或40〜500 單位/ml);其界面活性劑之濃度為〇丨〜]^ ^⑽ pg/ml，其濃度以1〜1，000 gg/ml較佳。 本發明進一步為有關於上述之醫藥組成 物，其甘油和/或甘露糖醇之濃度為1〇〇〜25〇 mM，和/或氣化物的濃度以150 mM較佳。 本發明進一步為有關於上述之醫藥组成 物’其緩衝物質的濃度為5〜250 mM。 本發明進一步為有關於一種藥用胰島素配 方，其進一步含例如鹽、魚精蛋白或Surfe^可 延遲胰島素釋放之添加物。上述延遲釋 双騰島 素配方之混合物亦包含於其中。 本發明進一步為有關於一種製備該醫藥組 成物的方法。本發明進一步同樣為有關於該配 方之投藥以治療糖尿病〇 Λ
-16- A7 B7 1301761 五、發明說明（15) 本發明進一步為有關於製備胰島素、胰島 素類似物、胰島素衍生物或其製劑的過程中使 用或添加界面活性劑做為其穩定劑。 所述之醫藥組成物中包括一種多肽，其選 自含膝島素、胰島素類似物、胰島素衍生物、 活性胰島素代謝物或其組合之族群，其pH介於 2和12之間，以介於6和8 · 5之間較佳，以介 於7和7.8之間最佳。 此專利申請案配合一些實施例之助說明如 下，其必需根據所述之方法操作。 實施例 經濟部智慧財產局員工消費合作社印製 比較研究：製備含HMR1964胰島素類似物 [離胺酸（B3)、麩胺酸（B29)、人類胰島素】之各 種無鋅製劑。製備完成後，將無辞HMR1964和 其它組成分溶於一份供注射用之水溶液中，以 及用鹽酸/氫氧化鈉將pH調整至7·3± 0.2，並製 成最終体積。下述各實驗中之HMR1964的濃度 為3.5 mg/ml(相當於1〇〇單位/mi)。以相同方法 製備第二製劑，但添加特殊量之界面活性劑。 將溶液分配於5 ml或1〇 ml玻璃容器（玻璃瓶） 中，並蓋上皇冠蓋。然後將這些玻璃瓶置於下 述之緊迫環境中： •17- 1301761
旋轉實驗：此旋轉實驗分成試驗組和對照 組，其各含5支玻璃瓶。將玻璃瓶置於離心器 内，並於37t：60rPm之下旋轉36〇。。在一定時 間之後，以標準濁度比較玻璃瓶内製劑之濁度 或利用實驗濁度光度計（濁度計）測定其 formazine濁度單位（FNU)。此實驗進行至全部 玻璃瓶達18 FNU濁度值為止 振盪實驗：將玻璃瓶置於保溫箱内之振盪 器上’並於30eC下以100次擺動/分鐘進行振 盪。在一定時間之後，利用實驗濁度光度計（濁 度計）測定測定樣本之formazine濁度單位 (FNU) 〇 實例1·旋轉實驗中添加鋅之jjMRI964的穩定 性 經 部 智 慧 財 產 局 員 工 消 费 合 作 社 印 (a)將無鋅HMR1964(最終配方之濃度為 3·5 mg/ml)溶於水溶液中，其最終濃度為27 mg/ml之m-甲苯酚、20 mg/ml之甘油和6 mg/ml 之Trometamoi(三羥甲基胺基甲烷/TRIS)，以及 利用1N(當量）鹽酸/in氫氧化鈉將pH調整至 7.2〜7,4(於室溫下）。以水將溶液配成最終体積， 並通過0·2 μπι之濾過器進行無菌過濾c然後將 其注入5 ml之注射瓶内，並以皇冠蓋加封。 -18- 經濟部智慧財產局員工消費合作社印製 1301761 a7 B7 五、發明說明（I7) (b)以相同方法製備對照溶液，但以水配製 之前加入相當於0.1 %強度之鋅氣化物儲備液， 而使最終配方之鋅含量為15 pg/ml。 各組以5件樣本進行旋轉實驗，然後在各 種不同時間測定其濁度。其結果列於下表： 說 明 濁度 >18 FNU之樣本數 胸碕 躱/J铸 第16,㈣ 餅'㈣ 第和摘 簌6狀 無添加物之 HMR1964 0 5 - - • - HMR1964+15pg/ml 辞 0 0 0 0 4 5 添加辞隨著時間增加可明顯延緩溶液濁度 之發生，因此可穩定HMR1964製劑。無添加辞 之製劑，甚至在第8小時之後即有明顯之混濁 發生。 實例2:旋轉實驗中添加聚山梨酸酯20(Τινββηφ) 之HMR1964的穩定性 (a)將無鋅HMR1964(最終配方之濃度為 3.5 mg/ml)溶於水溶液中，其最終濃度為3,15 mg/ml之 m_甲苯紛、5 mg/ml之氯化納和 6 mg/ml之Trometamol，以及利用 1N之鹽酸/1N 氫氧化鈉將pH調整至7.2〜7·4(於室溫下以水 將溶液配成最終体積，並通過0.2 μιη之濾過器 進行無菌過濾。然後將其注入5 ml之注射瓶 -19-
A7 B7 1301761 五、發明說明（1〇 内，並以皇冠蓋加封。 (b)以相同方法製備對照溶液，但以水配製 之前加入相當於 0.1%強度之聚山梨酸酯 20(Tweer^20)儲備液，而使最終配方之濃度為 1 0 pg/ml 〇 各組以5件樣本進行旋轉實驗，然後在各 種不同時間測定其濁度。其結果列於下表： 說 明 濁度>18 FNU之樣本數 第Μ碕 鄴4铸 第16⑽ 韌0批 無添加物之 HMR1964 0 5 - 虐 - - HMR1964+l(^g/ml 之 Tweenho 0 0 0 0 5 • 添加聚山梨酸酯20可明顯延緩溶液濁度之 發生。 實例 3: 旋轉實驗中添加 poloxamer 之 HMR1964的穩定性 (a) 將無鋅 HMR1964(最終配方之濃度為 經濟部智慧財產局員工消费合作社印製 3.5 mg/ml)溶於水溶液中，其最終濃度為 4.5 mg/ml之笨紛、5 mg/ml之氣化納和6 mg/ml之
Trometamol，以及利用1N之鹽酸/1N氫氧化納 將pH調整至7.2〜7.4(於室溫下）。以水將溶液配 成最終体積，並通過0.2 μιη之濾過器進行無菌 過濾。然後將其注入5 ml之注射瓶内，並以皇 -20- A7 B7 1301761 五、發明說明（19 ) 冠蓋加封。 (b)以相同方法製備對照溶液，但以水配製 之前加入相當於0.1%強度之poloxamer 171(例 如Genapol,儲備液，而使最終配方之鋅含量為 10 pg/m卜 各組以5件樣本進行旋轉實驗，然後在各 種不同時間測定其濁度。其結果列於下表： 說 明 濁度 >18 FNU之樣本數 躱摘 第16梢 粒Μ碣 ^40^ 無添加物之HMR1964 0 5 - - - - HMR1964+0,01mg/ml 之 poloxamer 171 0 0 0 2 5 _ 添加poloxamer 171亦可明顯延緩溶液濁度 之發生，並且可穩定製劑。 實例4:振盪實驗中添加聚山梨酸酯20或聚山 梨酸酯80之HMR1964的穩定性 經濟部智慧財產局員工消费合作社印製 (a) 將無鋅HMR1964(最終配方之濃度為 3,5 mg/ml)溶於水溶液中，其最終濃度為 3.15 mg/ml之 m-甲苯驗、5 mg/ml之氯化鈉和 6 mg/ml之Trometamol，以及利用 1N之鹽酸/1N 氫氧化鈉將pH調整至7.2〜7·4(於室溫下以水 將溶液配成最終体積，並通過0.2 μιη之濾過器 進行無菌過濾。然後將其注入5 ml之注射瓶 -21- A7 B7 1301761 五、發明說明（2〇) 内，並以皇冠蓋加封。 0>)以相同方法製備對照溶液，但以水配製 之前加入相當於 0.1%強度之聚山梨酸酯 20(Tween@20)儲備液，而使最終配方之濃度為 10 pg/ml 〇 (c)以（b)之相同方法製備另一對照溶液， 但以聚山梨酸酯 80(Τ\νββη®80)取代聚山梨酸酯 20 - 樣本於37乞之下置於振盪器（60rpm)上進行 振盪，然後在各種不同時間測定其濁度。其結 果列於下表： 添加物 振盪實驗後之濁（FNU) 開始 第1週 第2週 第3週 第4週 i添加 0.55 2.04 4,86 6.12 10.51 (K01mg/ml 之 Tween 20 1.75 2.60 2.44 2.44 3.80 0*01mg/ml 之 Tween 80 2.38 2.98 2.86 3.01 4.14 經濟部智慧財產局員工消费合作社印製 在振盪實驗中添加聚山梨酸酯20和聚山梨 酸酯80對HMR1 964均具有穩定效果。 實例 5:振盡實驗中添加鋅或 poloxamer (Genapol,之 HMR1964 的穩定性 (a) 將無鋅HMR1964(最终配方之濃度為 •22· 1301761 at ______B7_ 五、發明說明（21) 3.5 mg/ml)溶於水溶液中，其最終濃度為3.3 mg/ml之苯齡、5 mg/ml之氣化納和6 mg/ml之 Trometamol，以及利用1N之鹽酸/in氫氧化鈉 將pH調整至7.2〜7·4(於室溫下）。以水將溶液配 成最終体積，並通過0.2 μιη之濾過器進行無菌 過滤。然後將其注入5 ml之注射瓶内，並以皇 冠蓋加封。 (b) 以相同方法製備對照溶液，但以水配製 之前加入相當於 0,1%強度之 poloxamer PUGenapol®)儲備液，而使最終配方之濃度為 10 pg/ml〇 (c) 如（a)所述之方法製備另一對照溶液， 但以水配製之前溶液中加入相當於0.1%強度之 鋅氣化物以取代poloxamer，而使最終配方含15 gg/ml濃度之辞。 添加物 振盪實驗後之濁（FNU) 開始 第1週 第2週 第3週 第4週 無添加 0.39 0.70 4.46 8.74 14.11 (K01mg/ml 之 poloxamer 0.36 0.57 0.52 1.59 ~~一峰 0.89 0.015mg/ml 之鋅 1.02 0.68 0.70 0.56 0.86 經濟部智慧財產局員工消费合作社印製 在振盪實驗中添加辞和添加poloxamer均可 避免濁度之發生。 -23· A7 B7 1301761 五、發明說明（22) 實例 6: 旋轉實驗中添加 po丨oxamer 之 HMR1964的穩定性 (a) 將無鋅HMR1964(最終配方之濃度為 3,5 mg/ml)溶於水溶液中，其最終濃度為3.3 mg/ml之苯齡、5 mg/ml之氣化納和6 mg/ml之 Trometamol，以及利用1N之鹽酸/1N氫氧化鈉 將pH調整至7.2〜7.4(於室溫下以水將溶液配 成最終体積，並通過0·2 μπι之濾過器進行無菌 過濾。然後將其注入5 ml之注射瓶内，並以皇 冠蓋加封。 (b) 以相同方法製備對照溶液，但以水配製 之洳加入相當於 0.1%強度之 p〇l〇xarller l7l(Genapol,儲備液，而使最終配方之濃度為 100 pg/ml。 經濟部智慧財產局員工消费合作社印製 (c) 如（a)所述之方法製備另一對照溶液， 但以水配製之前溶液中加入相當於〇 i %強度之 鋅亂化物以取代poloxamer，而使最終配方含15 kg/ml濃度之鋅。 各組以5件樣本進行旋轉實驗，然後在各 種不同時間測定其濁度。其結果列於下表： -24- A7 B7 1301761 五、發明說明（23) 說 明 濁度 >18 FNU之樣本數 胸畴 勒树 第 16 笨24,㈣ 料 斜(H硪 無添加物之HMR1964 0 5 雜 - - - HMR1964+0.10mg/ml 之 poloxamer 171 0 0 0 0 1 5 添加100 pg/ml之poloxamer同樣明顯可穩 定HMR1964製劑。 經濟部智慧財產局員工消費合作社印製 -25-
Claims (1)
- 971301761 A8 B8 C8 D8 六、申請專利範圍 專利申請案第91105385號 ROC Patent Appln. No. 91105385 修正之申請專利範圍中文十替換頁-附件（二 Amended Claims in Chinese - Encl.HI) (民國97年3月7曰送呈） (Submitted on March 7, 2008) 經濟部智慧財產局員工消費合作社印製 • 一種具有增進穩定性之醫藥組成物，其包括胰島素類似 物Lys(B3)、Gln(B29)人類胰島素； 界面活性劑聚山梨酸酯； 其中此醫藥組成物為無鋅或含低於〇,4%重量比 之鋅，以組成物之胰島素含量為基準。2.如申請專利範圍第1項之醫藥組成物，其中胰島素類 似物之濃度為60〜6,000 nmol/ml。 3·如申請專利範圍第2項之醫藥組成物，其中胰島素類 似物之濃度為240〜3,000 nmol/ml。 4·如申請專利範圍第1項之醫藥組成物，其中界面活性 劑的濃度為0.1〜l，〇〇(^g/ml。 5· 如申請專利範圍第4項之醫藥組成物，其中界面活性 劑的濃度為1〜l，〇0(^g/m卜 6· 一種製造如申請專利範圍第1項之醫藥組成物的方 法，其中組成分係以水溶液形式混合一起，然後調 整所需之pH值’並以水將該混合物製成最終體積。 7·如申請專利範圍第6項之製造醫藥組成物的方法，其 最終濃度為3.15 mg/ml之甲苯酚、3.5 mg/ml之HMR 1964、6.0 mg/ml 之 Trometamo卜 5.0 mg/ml 之氣化鈉 和 〇·1 mg/ml 之 Tween⑧ 20 〇 -26 - 本紙張尺度翻+關家鮮(CNS)A4 規格（210x297公釐） 91067範圍-接3
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10114178A DE10114178A1 (de) | 2001-03-23 | 2001-03-23 | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI301761B true TWI301761B (en) | 2008-10-11 |
Family
ID=7678654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW091105385A TWI301761B (en) | 2001-03-23 | 2002-03-21 | Zinc-free and low-zinc insulin preparations having improved stability |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US6960561B2 (zh) |
| EP (2) | EP1381385B1 (zh) |
| JP (1) | JP4231292B2 (zh) |
| KR (2) | KR20100061868A (zh) |
| CN (1) | CN1273187C (zh) |
| AR (2) | AR033059A1 (zh) |
| AT (1) | ATE497777T1 (zh) |
| AU (1) | AU2002302409B2 (zh) |
| BR (1) | BRPI0208210B8 (zh) |
| CA (1) | CA2441260C (zh) |
| CY (2) | CY1111413T1 (zh) |
| DE (2) | DE10114178A1 (zh) |
| DK (2) | DK2289539T3 (zh) |
| ES (2) | ES2393180T3 (zh) |
| HR (1) | HRP20030765B1 (zh) |
| HU (1) | HU228847B1 (zh) |
| IL (2) | IL158057A0 (zh) |
| ME (1) | ME00408B (zh) |
| MX (1) | MXPA03007942A (zh) |
| MY (1) | MY129417A (zh) |
| NO (1) | NO326780B1 (zh) |
| NZ (1) | NZ528335A (zh) |
| PE (1) | PE20020968A1 (zh) |
| PL (1) | PL205465B1 (zh) |
| PT (2) | PT1381385E (zh) |
| RS (1) | RS51579B (zh) |
| RU (1) | RU2311922C2 (zh) |
| SI (1) | SI1381385T1 (zh) |
| TW (1) | TWI301761B (zh) |
| WO (1) | WO2002076495A1 (zh) |
| ZA (1) | ZA200306637B (zh) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9808285A (pt) * | 1997-03-20 | 2000-05-16 | Novo Nordisk As | Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| US20050250676A1 (en) * | 2001-11-19 | 2005-11-10 | Aventis Pharma Deutschland Gmbh | Method of activating insulin receptor substrate-2 to stimulate insulin production |
| DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| DE10250297A1 (de) * | 2002-10-29 | 2004-05-19 | Aventis Pharma Deutschland Gmbh | Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung |
| US7193035B2 (en) | 2002-10-29 | 2007-03-20 | Sanofi-Aventis Deutschland Gmbh | Crystals of insulin analogs and processes for their preparation |
| WO2004096266A1 (en) * | 2003-05-02 | 2004-11-11 | Novo Nordisk A/S | Improved physical stability of insulin formulations |
| EP2264065B1 (en) | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Novel insulin derivatives |
| JP4601627B2 (ja) * | 2004-01-16 | 2010-12-22 | バイオデル， インコーポレイテッド | 舌下薬物送達デバイス |
| EP1720520B1 (en) * | 2004-02-13 | 2010-06-09 | Nod Pharmaceuticals, Inc. | Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof |
| US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| ES2328048T3 (es) * | 2004-03-12 | 2009-11-06 | Biodel, Inc. | Composiciones de insulina con absorcion mejorada. |
| CN101027318B (zh) | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物，制剂及其用途 |
| JP2006087815A (ja) * | 2004-09-27 | 2006-04-06 | Canon Inc | 噴霧方法および該方法に基づく噴霧装置 |
| US20060194762A1 (en) * | 2004-12-23 | 2006-08-31 | Olaf Reer | Composition comprising an epothilone and methods for producing a composition comprising an epothilone |
| US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| PL1969004T3 (pl) * | 2005-12-28 | 2012-01-31 | Novo Nordisk As | Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji |
| US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| JP2009533471A (ja) | 2006-04-12 | 2009-09-17 | バイオデル， インコーポレイテッド | 即効型および長時間作用型組合せインスリン製剤 |
| US7714025B2 (en) * | 2006-05-10 | 2010-05-11 | Arizona Biomedical Research Commission | Modified chalcone compounds as antimitotic agents |
| US20100120660A1 (en) * | 2007-04-30 | 2010-05-13 | Per Balschmidt | Highly concentrated insulin solutions and compositions |
| ES2744384T3 (es) * | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
| CN101795680A (zh) * | 2007-11-16 | 2010-08-04 | 波苏蛋白试剂公司 | 稳定蛋白质的辅剂 |
| CN102026666B (zh) * | 2007-12-11 | 2013-10-16 | 常山凯捷健生物药物研发（河北）有限公司 | 促胰岛素肽缀合物制剂 |
| DK2229407T3 (en) | 2008-01-09 | 2017-02-27 | Sanofi Aventis Deutschland | NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE |
| KR101239008B1 (ko) * | 2008-03-31 | 2013-03-04 | 한양대학교 산학협력단 | 바일산 유도체 및 그의 응용 |
| JP2010063762A (ja) * | 2008-09-12 | 2010-03-25 | Yoshiharu Masui | 抗菌消臭剤 |
| CN103736082A (zh) | 2008-10-17 | 2014-04-23 | 赛诺菲-安万特德国有限公司 | 胰岛素和glp-1激动剂的组合 |
| MX2011004357A (es) | 2008-10-30 | 2011-05-23 | Novo Nordisk As | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario. |
| US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| RU2533217C3 (ru) * | 2009-06-26 | 2020-12-21 | Ново Нордиск А/С | Препарат, содержащий инсулин, никотинамид и аминокислоту |
| PH12011502708B1 (en) * | 2009-07-06 | 2017-11-10 | Sanofi Aventis Deutschland | Insulin preparations containing methionine |
| CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
| AU2010317995B2 (en) | 2009-11-13 | 2014-04-17 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine |
| CN101912600B (zh) * | 2010-01-11 | 2014-01-29 | 杨国汉 | 改善胰岛素在溶液中稳定性的方法 |
| PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
| JP6049625B2 (ja) | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー／エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| ES2550357T3 (es) | 2011-08-29 | 2015-11-06 | Sanofi-Aventis Deutschland Gmbh | Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| EP2771026A4 (en) | 2011-10-27 | 2015-08-05 | Univ Case Western Reserve | ULTRA-CONCENTRATED AND FAST-ACTING INSULIN ANALOG FORMULATIONS |
| WO2014076423A1 (fr) | 2012-11-13 | 2014-05-22 | Adocia | Formulation à action rapide d'insuline comprenant un composé anionique substitué |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| CN110354255B (zh) | 2013-04-03 | 2024-05-14 | 赛诺菲 | 通过长效胰岛素制剂治疗糖尿病 |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| AR098168A1 (es) * | 2013-10-25 | 2016-05-04 | Sanofi Sa | Formulación estable de insulina glulisina |
| RU2016132342A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных |
| KR20160104726A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형 |
| JP6735674B2 (ja) | 2014-01-09 | 2020-08-05 | サノフイＳａｎｏｆｉ | インスリンアスパルトの安定化された医薬製剤 |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| US10314911B2 (en) | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
| KR102578030B1 (ko) | 2014-12-12 | 2023-09-14 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린 글라진／릭시세나티드 고정비 제형 |
| TW201630622A (zh) | 2014-12-16 | 2016-09-01 | 美國禮來大藥廠 | 速效胰島素組合物 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| WO2017032795A1 (en) | 2015-08-25 | 2017-03-02 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| JP2018531899A (ja) | 2015-08-25 | 2018-11-01 | ノヴォ ノルディスク アー／エス | 新規インスリン誘導体及びその医学的使用 |
| BR112018002416A2 (pt) | 2015-08-25 | 2018-09-18 | Novo Nordisk As | derivados de insulina e seus usos médicos |
| JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| CN105749292A (zh) * | 2016-02-29 | 2016-07-13 | 苏州市贝克生物科技有限公司 | 促进胰岛素吸收的组合物及其制备方法 |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| EP3518893A1 (en) | 2016-09-29 | 2019-08-07 | Arecor Limited | Novel formulations |
| GB201707187D0 (en) | 2017-05-05 | 2017-06-21 | Arecor Ltd | Novel formulations |
| GB201707188D0 (en) | 2017-05-05 | 2017-06-21 | Arecor Ltd | Novel formulations |
| GB201707189D0 (en) | 2017-05-05 | 2017-06-21 | Arecor Ltd | Novel formulations |
| MX2019014195A (es) | 2017-06-01 | 2020-01-27 | Lilly Co Eli | Composiciones de insulina de rapida accion. |
| US12357562B2 (en) | 2018-04-04 | 2025-07-15 | Arecor Limited | Injection pen system for the delivery of an insulin compound |
| US20210093775A1 (en) | 2018-04-04 | 2021-04-01 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| WO2019193351A1 (en) | 2018-04-04 | 2019-10-10 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| FR3083700B1 (fr) * | 2018-07-13 | 2021-03-12 | Adocia | Formulation thermostable d'insuline humaine a21g |
| EP3883636A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CA3141488A1 (en) | 2019-05-22 | 2020-11-26 | Biovie Inc. | Formulations of terlipressin |
| JP7518149B2 (ja) | 2019-07-12 | 2024-07-17 | ノヴォ ノルディスク アー／エス | 高濃度インスリン製剤 |
| WO2021081404A1 (en) | 2019-10-25 | 2021-04-29 | Cercacor Laboratories, Inc. | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same |
| FI4073097T3 (fi) | 2019-12-11 | 2024-08-13 | Novo Nordisk As | Uusia insuliinianalogeja ja niiden käyttötapoja |
| EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| GB202004814D0 (en) | 2020-04-01 | 2020-05-13 | Arecor Ltd | Novel formulations |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3868358A (en) * | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| US3758683A (en) * | 1971-04-30 | 1973-09-11 | R Jackson | Insulin product |
| US4153689A (en) * | 1975-06-13 | 1979-05-08 | Takeda Chemical Industries, Ltd. | Stable insulin preparation for nasal administration |
| GB1527605A (en) | 1975-08-20 | 1978-10-04 | Takeda Chemical Industries Ltd | Insulin preparation for intranasal administration |
| EP0018609B1 (de) | 1979-04-30 | 1983-09-21 | Hoechst Aktiengesellschaft | Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| JPS55153712A (en) | 1979-05-18 | 1980-11-29 | Kao Corp | Insulin pharmaceutical preparation and its production |
| DE3033127A1 (de) | 1980-09-03 | 1982-04-08 | Hoechst Ag, 6000 Frankfurt | Neue analoga des insulins |
| AU558474B2 (en) | 1981-07-17 | 1987-01-29 | Nordisk Insulinlaboratorium | A stable aqueous, therapeutic insulin preparation and a process for preparing it |
| NL193099C (nl) * | 1981-10-30 | 1998-11-03 | Novo Industri As | Gestabiliseerde insuline-oplossing. |
| DE3316363A1 (de) | 1983-05-05 | 1984-11-08 | Deutsche Babcock Anlagen Ag, 4200 Oberhausen | Walzenrost fuer muellverbrennungsanlagen |
| DE3326472A1 (de) * | 1983-07-22 | 1985-02-14 | Hoechst Ag, 6230 Frankfurt | Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus |
| DE3326473A1 (de) * | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
| DE3327709A1 (de) * | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
| DE3327713A1 (de) | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Wasserloesliche disazoverbindungen, verfahren zu deren herstellung und ihre verwendung als farbstoffe |
| CA1244347A (en) * | 1984-05-29 | 1988-11-08 | Eddie H. Massey | Stabilized insulin formulations |
| US4839341A (en) * | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| DE3576120D1 (de) | 1984-06-09 | 1990-04-05 | Hoechst Ag | Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung. |
| KR860001166B1 (ko) * | 1984-06-15 | 1986-08-20 | 곽성일 | 신발 결착용 구멍쇠의 제조방법 |
| DE3440988A1 (de) | 1984-11-09 | 1986-07-10 | Hoechst Ag, 6230 Frankfurt | Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung |
| DK347086D0 (da) | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
| US5008241A (en) * | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
| DK113585D0 (da) | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
| EP0200383A3 (en) * | 1985-04-15 | 1987-09-02 | Eli Lilly And Company | An improved method for administering insulin |
| DE3526995A1 (de) | 1985-07-27 | 1987-02-05 | Hoechst Ag | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| US5496924A (en) | 1985-11-27 | 1996-03-05 | Hoechst Aktiengesellschaft | Fusion protein comprising an interleukin-2 fragment ballast portion |
| DE3541856A1 (de) | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
| CA1275922C (en) | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
| DE3544295A1 (de) * | 1985-12-14 | 1987-06-19 | Bayer Ag | Thermoplastische formmassen mit hoher kriechstromfestigkeit |
| PH23446A (en) * | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| FI884914A0 (fi) | 1987-02-25 | 1988-10-24 | Novo Industri As | Nya insulinderivat. |
| US5034415A (en) * | 1987-08-07 | 1991-07-23 | Century Laboratories, Inc. | Treatment of diabetes mellitus |
| DE3726655A1 (de) * | 1987-08-11 | 1989-02-23 | Hoechst Ag | Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten |
| DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
| US6875589B1 (en) * | 1988-06-23 | 2005-04-05 | Hoechst Aktiengesellschaft | Mini-proinsulin, its preparation and use |
| DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
| DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| JPH04502465A (ja) | 1988-12-23 | 1992-05-07 | ノボ ノルディスク アクティーゼルスカブ | ヒトインシュリン類似物質 |
| US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| IL93282A (en) | 1989-02-09 | 1995-08-31 | Lilly Co Eli | Insulin analogues |
| US5358857A (en) * | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
| DK0532546T3 (da) * | 1990-05-10 | 1998-12-28 | Nycomed Pharma As | Farmaceutisk præparat indeholdende N-glycofuroler og N-ethylenglycoler |
| US5397771A (en) * | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
| DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
| DK10191D0 (da) * | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
| US6468959B1 (en) * | 1991-12-05 | 2002-10-22 | Alfatec-Pharm Gmbh | Peroral dosage form for peptide containing medicaments, in particular insulin |
| ES2087565T3 (es) * | 1991-12-05 | 1996-07-16 | Alfatec Pharma Gmbh | Nanosol aplicable farmaceuticamente y procedimiento para su preparacion. |
| US5614219A (en) * | 1991-12-05 | 1997-03-25 | Alfatec-Pharma Gmbh | Oral administration form for peptide pharmaceutical substances, in particular insulin |
| DE59305396D1 (de) * | 1992-12-02 | 1997-03-20 | Hoechst Ag | Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken |
| AU680462B2 (en) | 1992-12-18 | 1997-07-31 | Eli Lilly And Company | Insulin analogs |
| DE4400709B4 (de) * | 1993-01-13 | 2005-06-23 | Denso Corp., Kariya | Schraubenfestziehvorrichtung |
| US5606203A (en) * | 1993-01-20 | 1997-02-25 | Kabushiki Kaisha Toshiba | Semiconductor device having Al-Cu wiring lines where Cu concentration is related to line width |
| US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
| DE4405179A1 (de) * | 1994-02-18 | 1995-08-24 | Hoechst Ag | Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5559094A (en) * | 1994-08-02 | 1996-09-24 | Eli Lilly And Company | AspB1 insulin analogs |
| EP0779806B2 (en) | 1994-09-09 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Sustained release preparation containing metal salt of a peptide |
| US5547929A (en) * | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| US5824638A (en) * | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| JP2002514892A (ja) | 1995-06-08 | 2002-05-21 | コブラ セラピューティクス リミテッド | 遺伝子治療における合成ウイルス様粒子の使用 |
| WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| DE19545257A1 (de) * | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| DE19707245A1 (de) * | 1997-02-25 | 1998-08-27 | Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh | Verfahren zur Herstellung einer elektrischen Glühlampe |
| BR9808285A (pt) * | 1997-03-20 | 2000-05-16 | Novo Nordisk As | Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus |
| US6310038B1 (en) * | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
| US6043214A (en) * | 1997-03-20 | 2000-03-28 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
| CO4750643A1 (es) | 1997-06-13 | 1999-03-31 | Lilly Co Eli | Formulacion estable de la insulina que contiene l-arginina y protamina |
| DE19726167B4 (de) * | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| ZA989744B (en) * | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| AU1375199A (en) | 1997-11-12 | 1999-05-31 | Alza Corporation | Method for decreasing self-association of polypeptides |
| EP1044016B1 (en) * | 1998-01-09 | 2005-03-16 | Novo Nordisk A/S | Stabilised insulin compositions |
| HUP0104111A3 (en) | 1998-10-16 | 2002-05-28 | Novo Nordisk As | Stable concentrated insulin preparations for pulmonary delivery |
| IL142002A0 (en) | 1998-10-16 | 2002-03-10 | Novo Nordisk As | Insulin preparation for pulmonary delivery containing menthol |
| US6635617B1 (en) * | 1998-10-16 | 2003-10-21 | Novo Nordisk A/S | Insulin preparations for pulmonary delivery containing menthol |
| US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| US6489292B1 (en) * | 1998-11-18 | 2002-12-03 | Novo Nordisk A/S | Stable aqueous insulin preparations without phenol and cresol |
| JP2002529514A (ja) | 1998-11-18 | 2002-09-10 | ノボ ノルディスク アクティーゼルスカブ | フェノール及びクレゾールを要さない安定なインスリン水性調製物 |
| DE19908041A1 (de) * | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2000074736A1 (en) * | 1999-06-04 | 2000-12-14 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| WO2001000223A2 (en) | 1999-06-25 | 2001-01-04 | Minimed Inc. | Multiple agent diabetes therapy |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| JP2003509453A (ja) | 1999-09-21 | 2003-03-11 | アールティーピー・ファーマ・インコーポレーテッド | 生物学的に活性な物質の、表面改質された粒状組成物 |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| AU2001220765A1 (en) | 2000-01-24 | 2001-07-31 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
| WO2001093837A2 (en) | 2000-06-08 | 2001-12-13 | Eli Lilly And Company | Protein powder for pulmonary delivery |
| KR100508695B1 (ko) | 2001-02-13 | 2005-08-17 | 한국과학기술연구원 | 인슐린의 경구투여용 제형과 그의 제조방법 |
| DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| CN1160122C (zh) | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
| US20040265268A1 (en) * | 2001-08-18 | 2004-12-30 | Deepak Jain | Compositions and methods for skin rejuvenation and repair |
| WO2003035051A2 (en) | 2001-10-19 | 2003-05-01 | Inhale Therapeutic Systems, Inc. | The use of proton sequestering agents in drug formulations |
| WO2003035028A1 (en) | 2001-10-19 | 2003-05-01 | Nektar Therapeutics | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
| US20060287221A1 (en) * | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
-
2001
- 2001-03-23 DE DE10114178A patent/DE10114178A1/de not_active Ceased
-
2002
- 2002-03-09 AU AU2002302409A patent/AU2002302409B2/en not_active Expired
- 2002-03-09 PT PT02729985T patent/PT1381385E/pt unknown
- 2002-03-09 HR HR20030765A patent/HRP20030765B1/xx not_active IP Right Cessation
- 2002-03-09 NZ NZ528335A patent/NZ528335A/en not_active IP Right Cessation
- 2002-03-09 WO PCT/EP2002/002625 patent/WO2002076495A1/de not_active Ceased
- 2002-03-09 BR BR0208210-1 patent/BRPI0208210B8/pt not_active IP Right Cessation
- 2002-03-09 ES ES10178836T patent/ES2393180T3/es not_active Expired - Lifetime
- 2002-03-09 EP EP02729985A patent/EP1381385B1/de not_active Expired - Lifetime
- 2002-03-09 RU RU2003131187/15A patent/RU2311922C2/ru active
- 2002-03-09 SI SI200230934T patent/SI1381385T1/sl unknown
- 2002-03-09 CA CA2441260A patent/CA2441260C/en not_active Expired - Lifetime
- 2002-03-09 HU HU0303596A patent/HU228847B1/hu unknown
- 2002-03-09 RS YU73503A patent/RS51579B/sr unknown
- 2002-03-09 PT PT10178836T patent/PT2289539E/pt unknown
- 2002-03-09 EP EP10178836A patent/EP2289539B1/de not_active Expired - Lifetime
- 2002-03-09 ME MEP-2008-608A patent/ME00408B/me unknown
- 2002-03-09 DK DK10178836.2T patent/DK2289539T3/da active
- 2002-03-09 PL PL362800A patent/PL205465B1/pl unknown
- 2002-03-09 DE DE50214903T patent/DE50214903D1/de not_active Expired - Lifetime
- 2002-03-09 KR KR1020107011428A patent/KR20100061868A/ko not_active Ceased
- 2002-03-09 ES ES02729985T patent/ES2360505T3/es not_active Expired - Lifetime
- 2002-03-09 KR KR1020037012339A patent/KR100987311B1/ko not_active Expired - Lifetime
- 2002-03-09 JP JP2002575008A patent/JP4231292B2/ja not_active Expired - Lifetime
- 2002-03-09 CN CNB02807114XA patent/CN1273187C/zh not_active Expired - Lifetime
- 2002-03-09 DK DK02729985.8T patent/DK1381385T3/da active
- 2002-03-09 MX MXPA03007942A patent/MXPA03007942A/es active IP Right Grant
- 2002-03-09 IL IL15805702A patent/IL158057A0/xx unknown
- 2002-03-09 AT AT02729985T patent/ATE497777T1/de active
- 2002-03-21 AR ARP020101020A patent/AR033059A1/es not_active Application Discontinuation
- 2002-03-21 TW TW091105385A patent/TWI301761B/zh not_active IP Right Cessation
- 2002-03-22 US US10/102,862 patent/US6960561B2/en not_active Expired - Lifetime
- 2002-03-22 PE PE2002000226A patent/PE20020968A1/es not_active Application Discontinuation
- 2002-03-22 MY MYPI20021031A patent/MY129417A/en unknown
-
2003
- 2003-08-26 ZA ZA200306637A patent/ZA200306637B/xx unknown
- 2003-09-16 NO NO20034125A patent/NO326780B1/no not_active IP Right Cessation
- 2003-09-22 IL IL158057A patent/IL158057A/en active IP Right Grant
-
2004
- 2004-12-09 US US11/007,155 patent/US7205277B2/en not_active Expired - Lifetime
- 2004-12-09 US US11/007,154 patent/US7205276B2/en not_active Expired - Lifetime
-
2007
- 2007-03-08 US US11/683,747 patent/US7452860B2/en not_active Expired - Lifetime
-
2008
- 2008-10-06 US US12/285,464 patent/US7696162B2/en not_active Expired - Lifetime
-
2011
- 2011-03-03 CY CY20111100253T patent/CY1111413T1/el unknown
-
2012
- 2012-11-08 CY CY20121101060T patent/CY1113318T1/el unknown
-
2014
- 2014-05-21 AR ARP140102020A patent/AR096376A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI301761B (en) | Zinc-free and low-zinc insulin preparations having improved stability | |
| ES2992698T3 (en) | Combination of an insulin and a glp-1 agonist | |
| JP5675799B2 (ja) | 遅効性インスリン製剤 | |
| TW200409642A (en) | Acidic insulin preparations having improved stability | |
| JPH02101022A (ja) | 糖尿病治療用医薬組成物 | |
| JP2005538068A (ja) | 高濃度のヒト成長ホルモン（ｈＧＨ）とフェノールを含有する液剤 | |
| JP2012233003A (ja) | 単量体インスリン及びアシル化インスリンを含む可溶性製剤 | |
| JP2012532178A (ja) | メチオニンを含むインスリン製剤 | |
| JP2012532177A (ja) | 熱及び振動安定性インスリン製剤 | |
| AU2013368990B2 (en) | Pharmaceutical composition | |
| HK1061521B (zh) | 稳定性提高的无锌或低锌胰岛素制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |